The biopharmaceutical company Bristol Myers Squibb (BMS) placed hypertrophic cardiomyopathy at the core of a recent Nicosia press conference, held under the auspices of the Cyprus Society of Cardiology.
Cypriot cardiologists specialising in the condition highlighted its clinical aspects, symptomatology and the importance of timely diagnosis and effective management in improving patients’ quality of life.
Hypertrophic cardiomyopathy is one of the most common cardiomyopathies and is characterised by excessive thickening
